Chris M. Pillar

2.0k total citations
45 papers, 1.4k citations indexed

About

Chris M. Pillar is a scholar working on Molecular Medicine, Infectious Diseases and Pharmacology. According to data from OpenAlex, Chris M. Pillar has authored 45 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Medicine, 22 papers in Infectious Diseases and 18 papers in Pharmacology. Recurrent topics in Chris M. Pillar's work include Antibiotic Resistance in Bacteria (23 papers), Antibiotics Pharmacokinetics and Efficacy (17 papers) and Antimicrobial Resistance in Staphylococcus (16 papers). Chris M. Pillar is often cited by papers focused on Antibiotic Resistance in Bacteria (23 papers), Antibiotics Pharmacokinetics and Efficacy (17 papers) and Antimicrobial Resistance in Staphylococcus (16 papers). Chris M. Pillar collaborates with scholars based in United States, Canada and Germany. Chris M. Pillar's co-authors include Daniel F. Sahm, Wolfgang Haas, Deborah C. Draghi, Timothy W. Morris, Dean L. Shinabarger, Gary E. Zurenko, Kevin M. Krause, Karen Joy Shaw, Clyde Thornsberry and D.F. Sahm and has published in prestigious journals such as The EMBO Journal, PLoS ONE and Journal of Clinical Microbiology.

In The Last Decade

Chris M. Pillar

43 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris M. Pillar United States 23 623 573 484 341 291 45 1.4k
Deborah C. Draghi United States 22 783 1.3× 742 1.3× 447 0.9× 362 1.1× 546 1.9× 33 1.9k
Flávia Rossi Brazil 24 469 0.8× 530 0.9× 233 0.5× 187 0.5× 233 0.8× 92 1.3k
S D Allen United States 20 487 0.8× 218 0.4× 186 0.4× 293 0.9× 252 0.9× 53 1.3k
Michael Kresken Germany 21 448 0.7× 669 1.2× 426 0.9× 272 0.8× 310 1.1× 73 1.4k
Francis S. Codjoe Ghana 10 186 0.3× 533 0.9× 166 0.3× 93 0.3× 133 0.5× 14 1.1k
C C Knapp United States 24 1.1k 1.8× 335 0.6× 372 0.8× 192 0.6× 329 1.1× 49 1.7k
Eugenio A. Debbia Italy 21 577 0.9× 541 0.9× 312 0.6× 271 0.8× 251 0.9× 94 1.6k
Jennifer M Streit United States 25 1.0k 1.7× 782 1.4× 509 1.1× 364 1.1× 674 2.3× 73 1.8k
N X Chin United States 28 633 1.0× 979 1.7× 1.4k 2.8× 412 1.2× 280 1.0× 62 2.3k
Arthur L. Barry United States 25 695 1.1× 844 1.5× 939 1.9× 331 1.0× 591 2.0× 117 2.1k

Countries citing papers authored by Chris M. Pillar

Since Specialization
Citations

This map shows the geographic impact of Chris M. Pillar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris M. Pillar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris M. Pillar more than expected).

Fields of papers citing papers by Chris M. Pillar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris M. Pillar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris M. Pillar. The network helps show where Chris M. Pillar may publish in the future.

Co-authorship network of co-authors of Chris M. Pillar

This figure shows the co-authorship network connecting the top 25 collaborators of Chris M. Pillar. A scholar is included among the top collaborators of Chris M. Pillar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris M. Pillar. Chris M. Pillar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jahanbakhsh, Sareh, et al.. (2023). Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages. JAC-Antimicrobial Resistance. 5(5). dlad104–dlad104. 4 indexed citations
2.
Brothers, Kimberly M., Jonathan B. Mandell, Masashi Taguchi, et al.. (2022). Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class. PLoS ONE. 17(9). e0274815–e0274815. 22 indexed citations
3.
Cotroneo, Nicole, et al.. (2020). 1274. Evaluating the Activity of SPR719, a Novel Aminobenzimidazole, against Nontuberculous Mycobacteria. Open Forum Infectious Diseases. 7(Supplement_1). S653–S654. 1 indexed citations
4.
Hall, Devon, Dean L. Shinabarger, Alisa W. Serio, et al.. (2018). Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease. 92(4). 338–345. 23 indexed citations
5.
Shinabarger, Dean L., et al.. (2017). Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines. Diagnostic Microbiology and Infectious Disease. 89(1). 83–85. 4 indexed citations
6.
Shinabarger, Dean L., et al.. (2017). In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.. Diagnostic Microbiology and Infectious Disease. 89(3). 205–211. 18 indexed citations
7.
Shinabarger, Dean L., et al.. (2016). Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease. 87(2). 121–128. 24 indexed citations
8.
9.
Silley, P., et al.. (2012). Susceptibility of coagulase-negative staphylococci to a kanamycin and cefalexin combination. Journal of Dairy Science. 95(6). 3448–3453. 5 indexed citations
10.
Queenan, Anne Marie, Chris M. Pillar, Jennifer Deane, et al.. (2012). Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagnostic Microbiology and Infectious Disease. 73(3). 267–270. 65 indexed citations
11.
Haas, Wolfgang, Chris M. Pillar, Christine K. Hesje, Christine M. Sanfilippo, & Timothy W. Morris. (2011). In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride. Journal of Antimicrobial Chemotherapy. 66(4). 840–844. 20 indexed citations
12.
Davies, Todd A., Anne Marie Queenan, Brian J. Morrow, et al.. (2011). Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007–09. Journal of Antimicrobial Chemotherapy. 66(10). 2298–2307. 80 indexed citations
13.
Haas, Wolfgang, Chris M. Pillar, Christine K. Hesje, Christine M. Sanfilippo, & Timothy W. Morris. (2010). Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. Journal of Antimicrobial Chemotherapy. 65(7). 1441–1447. 49 indexed citations
14.
Pillar, Chris M., et al.. (2009). Evaluating the in vitro susceptibility of bovine mastitis pathogens to a combination of kanamycin and cefalexin: Recommendations for a disk diffusion test. Journal of Dairy Science. 92(12). 6217–6227. 12 indexed citations
15.
Pillar, Chris M.. (2008). Mode of Action of CXA-101 Based on Minimum Bactericidal Concentration (MBC) Analysis and Timekill Kinetic (TK) Analysis. 46th Annual Meeting. 1 indexed citations
16.
Pillar, Chris M., et al.. (2008). In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. Journal of Antimicrobial Chemotherapy. 61(3). 595–602. 48 indexed citations
17.
Shaw, Karen Joy, Susan M. Poppe, Ronda D. Schaadt, et al.. (2008). In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains. Antimicrobial Agents and Chemotherapy. 52(12). 4442–4447. 153 indexed citations
18.
Draghi, Deborah C., Bret M. Benton, Kevin M. Krause, et al.. (2008). In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. Journal of Antimicrobial Chemotherapy. 62(1). 116–121. 53 indexed citations
19.
Shankar, Nathan, Phillip S. Coburn, Chris M. Pillar, Wolfgang Haas, & Michael S. Gilmore. (2004). Enterococcal cytolysin: activities and association with other virulence traits in a pathogenicity island. International Journal of Medical Microbiology. 293(7-8). 609–618. 46 indexed citations
20.
Pillar, Chris M., Linda D. Hazlett, & J A Hobden. (2000). Alkaline protease-deficient mutants of Pseudomonas aeruginosa are virulent in the eye. Current Eye Research. 21(3). 730–739. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deborah C. Draghi Breakdown of academic impact, for papers by Flávia Rossi Breakdown of academic impact, for papers by S D Allen Breakdown of academic impact, for papers by Michael Kresken Breakdown of academic impact, for papers by Francis S. Codjoe Breakdown of academic impact, for papers by C C Knapp Breakdown of academic impact, for papers by Eugenio A. Debbia Breakdown of academic impact, for papers by Jennifer M Streit Breakdown of academic impact, for papers by N X Chin Breakdown of academic impact, for papers by Arthur L. Barry
Rankless by CCL
2026